In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance by Vliegen, Inge et al.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1 
 
 
 
In vitro combinations containing Tegobuvir are highly efficient in curing cells from 
HCV replicon and in delaying/preventing the development of drug resistance 
 
 
Inge Vliegen
1
, Jan Paeshuyse
1
, Weidong Zhong
2,+ 
and Johan Neyts
1,
*
 
1
Rega Institute, Leuven, Belgium;  
2
Gilead Sciences, Inc., Foster City, CA, USA 
 
Short title: Tegobuvir combination studies 
 
*Corresponding author: Tel. 32-16-337341. Fax: 32-16-337340. E-mail:  
johan.neyts@rega.kuleuven.be; 
+
Current address: Novartis Institute for BioMedical Research, 
Emeryville, CA 
 
List of abbreviations: DAA: direct acting antivirals; SOC; standard of care; Peg_IFN: pegylated 
interferon; RBV: ribavirin; RVR: rapid virological response; cEVR: complete early virological reponse; 
vRVR: very rapid viral response; 2’-C-MeCyt: 2’-C-methylcytidine; TCA: Thiophene carboxylic acid;  
EC50: 50% effective concentration; CC50: 50 % cytotoxic concentration;  
*Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
ABSTRACT  
Tegobuvir (GS-9190) is a non-nucleoside inhibitor of HCV RNA replication with proven antiviral activity 
in HCV-infected patients. The in vitro antiviral activity of Tegobuvir, when combined with one or two 
other direct acting antivirals (DAA) was assessed. When Tegobuvir was combined with either 
interferon -2b, ribavirin, the protease inhibitor (PI) VX-950, the nucleoside polymerase inhibitor (NI) 
2’-C-methylcytidine or various non-nucleoside polymerase inhibitors, an overall additive antiviral 
activity was observed. Adding Tegobuvir (at concentrations of 6, 30 or 150 nM) to replicon-containing 
cells in the presence of suboptimal concentrations of the PI or of the various polymerase inhibitors 
either markedly delayed or completely prevented resistance development against these latter 
compounds. Tegobuvir (15 nM), when combined with the PI, was able to cure replicon-containing cells 
from their replicon after a single passage, whereas either compound alone (at 2-fold higher 
concentration) was not. The triple combination of Tegobuvir (10 nM), the PI and the NI resulted in 
clearance of replicon RNA after only two passages. In contrast, the inhibitors when used alone at 3-
fold higher concentrations were not able to cure the cells from the replicon, after as long as 6 
passages. Combinations containing low concentrations of Tegobuvir are thus highly effective in curing 
cells from HCV replicon and in delaying or preventing the development of resistance against other 
DAA.   
Keywords: HCV, combination therapy, Tegobuvir, DAA, resistance development, cell curing 
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1. Introduction 
In the past decade, the standard of care (SOC) of chronic HCV infection consisted of the combination 
of pegylated interferon (Peg-IFN) and ribavirin (RBV). As this therapy was only effective in 50-60% of 
genotype 1 infected patients and was associated with serious side effects (Manns et al., 2006), major 
efforts were made to develop highly potent and better tolerated inhibitors of HCV replication. Since 
early 2011, the NS3 protease inhibitors Telaprevir and Boceprevir have been added to the Peg-IFN 
/RBV regimen which significantly improved the sustained virological response. There are also a 
number of second generation direct acting antivirals (DAA) which are currently under clinical 
development (Asselah & Marcellin, 2012; Sarrazin et al., 2012). In addition, several studies in which 
IFN-free DAA combinations are being evaluated, with or without ribavirin, are currently on-going and 
some of which have produced preliminary but encouraging data. The INFORM-1 trial was the first 
proof-of-concept study to investigate the antiviral efficacy of an all-oral, interferon-free combination 
therapy, consisting of the high resistance barrier nucleoside polymerase inhibitor R7128 and NS3/4A 
protease inhibitor ITMN-191, in patients with chronic hepatitis C (Gane et al., 2009). In this short-term 
(14 days of treatment) study, no evidence of treatment-emerging resistance to either compound was 
identified and 99% of the patients in the treatment group had a continuous decline in viral load. The 
success of the INFORM-1 study demonstrated that IFN-free therapy against chronic HCV infection 
could become reality in the future. However, subsequent studies, in which drugs with low barriers to 
resistance such as an NS3/4A protease inhibitor with an NS5A inhibitor or a non-nucleoside inhibitor 
were combined, resulted in rather disappointing efficacies (Foster et al., 2011; Lok et al., 2012). 
Treatment failure caused by the emergence of viral variants carrying drug resistance mutations was 
frequent. Despite of the setbacks, it remains quite possible that drug resistance can be overcome by 
using (i) triple or quadruple DAA combinations or, (ii) combinations including at least one molecule 
with a high barrier to resistance.  
Tegobuvir (GS-9190) is a potent and selective inhibitor of HCV genotype 1 replication. 
Resistance mutations (C316Y, C445F, Y448H, Y452H) are located close to the NS5B active site with 
C445F, Y448H and Y452H located in the β-hairpin region of NS5B (Bae et al., 2010; Shih et al., 
2011). Cross-resistance analyses with the site III inhibitor A-782759 and site IV inhibitor HCV-796 
revealed that Tegobuvir acts via a mechanism that is different from that of other non-nucleoside HCV 
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polymerase inhibitors (Shih et al., 2011). Tegobuvir undergoes a CYP 1A- mediated intracellular 
activation step; the resulting metabolite, after forming a glutathione conjugate, directly and specifically 
interacts with and inhibits NS5B (Hebner et al., 2012). When administered in combination with Peg-
IFN/RBV in treatment naive GT1 patients, Tegobuvir (40mg BID) increased RVR (rapid virological 
response) by ~30% and cEVR (complete early virological reponse) by ~20% over Peg-IFN/RBV 
treatment although, no improvement in SVR was observed in the final analysis (Lawitz et al., 2011). 
Viral rebound and relapse were associated with the appearance of the NS5B Y448H mutant (Hebner 
et al., 2011). Tegobuvir, when combined with a NS3 protease inhibitor GS-9256 and Peg-IFN/RBV, 
resulted in 100% RVR (14 of 14 patients) in a small study (Zeuzem et al., 2012). Three additional 
phase II clinical trials are ongoing (GS-US-248-120, GS-US-248-0132, GS-US-248-0131) wherein the 
combined effect of 3 DAA combinations (the NS5A inhibitor GS-5885, the protease inhibitor GS-9451 
and Tegobuvir) plus ribavirin were evaluated. Interim results indicate high on treatment response rates 
with the 12-24 week, IFN-free, all-oral quad regimen in HCV GT1a and 1b patients (Sulkowski et al., 
2012). Despite these encouraging results development of Tegobuvir was not continued. 
The rationale of the present study was (i) to assess the barrier to resistance of DAA combinations 
containing tegobuvir in replicon cells, (ii) to gain insight into the phenotype and genotype of potential 
multiple drug-resistant variants, and (iii) to assess the efficacy of triple combinations containing 
Tegobuvir, a nucleoside polymerase inhibitor and a NS3 protease inhibitor.   
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2. Materials and Methods 
2.1. Cell culture 
Huh 9-13 cells (Huh 7 cells containing the subgenomic HCV replicon I377/NS3-3′/wt (Lohmann et 
al., 1999)), HuH6 cells (Huh 7 cells containing the subgenomic HCV replicon I389luc-ubi-neo/NS3-3′/5.1 
(Windisch et al., 2005)) or Huh 5-2 cells (Huh 7 cells carrying the subgenomic HCV replicon I389luc-
ubi-neo/NS3-3’/5.1 (Vrolijk et al., 2003)) were cultured as described before (Vliegen et al., 2009).  
2.2. HCV Inhibitors  
The HCV NS5B polymerase inhibitors 2’-C-MeCyt (2’-C-methylcytidine), JT-16 (site I, 
benzimidazole), TCA (site II, Thiophene carboxylic acid), HCV-796 (site IV, benzofuran) and the NS3 
protease inhibitor VX-950 were synthesized according to procedures reported in publications 
referenced in (Paeshuyse et al., 2008). Ribavirin was purchased from ICN Pharmaceuticals (Costa 
Mesa, California) and recombinant IFNα 2b (intron® A) was purchased from Schering Plough 
(Kenilworth, NJ). The synthesis of both GS-327073 (5-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-2-(2,3-
difluorophenyl)-5H-imidazo[4,5-c]pyridine) and GS-9190 (5-({6-[2,4-
bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine) has 
been described in the patent literature (Bondy et al., 2005, 2007, 2008a,b).  
2.3. Antiviral and cytostatic assays 
 Antiviral and cytostatic assays were performed as described before (Paeshuyse et al., 2008). For 
Huh 5-2 cells, the EC50 was defined as the concentration of compound that reduced the firefly 
luciferase signal by 50 %; for Huh 9-13 and HuH6 cells as the concentration of compound that 
reduced the amount of HCV RNA by 50 %. The 50 % cytotoxic concentration (CC50), that is defined as 
the concentration that inhibits the proliferation of exponentially growing cells by 50 %, was determined 
using the MTS/PMS method.  
2.4. Combination antiviral assay 
Combination antiviral assays were performed in HuH6 cells in a checkerboard format according 
to the protocol as described before (Vliegen et al., 2009). In HuH6 replicon-containing cells replication 
of the replicon is largely independent of cell proliferation, which is important when planning 
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combination studies with a cytostatic drug such as ribavirin (Windisch et al., 2005). The effect of drug-
drug combinations were evaluated using the MacSynergy II software developed by Prichard and 
Shipman, analyzing data for synergism, antagonism, or additive effects (Prichard and Shipman, 1990).  
2.5. Combined resistance selection 
Combined resistance selection was performed using Huh 9-13 replicon-containing cells seeded in 
a 12-well plate as described before (Delang et al., 2009). Cells were seeded in complete DMEM 
containing 1 mg/ml G418 and in the presence of GS-9190 (6, 30 or 150 nM), VX-950 (3 or 6 µM), 2’-C-
MeCyt (2 or 11 µM), JT-16 (4 or 10 µM), TCA (3 or 15 µM), HCV-796 (2 or 12 µM) or a combination of 
GS-9190 with either one of the other molecules in a matrix format. Following 3 weeks of selection, 
cultures were either fixed with ethanol and stained with 1% methylene blue or were expanded to 
obtain sufficient cells for subsequent phenotyping (antiviral assay) and genotypic characterization. 
2.6. Clearance-rebound assay 
Clearance–rebound assays were performed using Huh 9-13 cells as described before (Vliegen et 
al., 2009). To compare the effect of single, double and triple combinations, a total compound 
concentration of 25 x EC50 was added to the cultures [either as a sum of 8.3 x + 8.3 x +8.3 x EC50 or 
as a sum of 12.5 x + 12.5 x EC50 or as a single concentration of 25 x EC50]. In addition, for reasons of 
comparison, conditions with a single concentration of 8.3 x or 25 x EC50 [VX-950, 2’-C-MeCyt or GS-
9190] or 125 x EC50 [GS-9190] were included. In total, cells were passaged six consecutive times in 
the presence or absence of compound(s) and in the absence of G418. Following every passage in the 
presence of antiviral pressure, cells of each tissue culture flask were passaged for four consecutive 
times in the absence of the antiviral molecules but in the presence of 1 mg/mL G418 (rebound phase). 
At each passage, 3 × 10
5
 cells were seeded in 25 cm
2
 tissue culture flasks and 1.5 × 10
5
 cells from 
each flask were lysed in RLT buffer. After collecting all samples, RNA was extracted using the RNeasy 
minikit (Qiagen, Venlo, the Netherlands) and replicon RNA content was quantified by means of RT-
qPCR. 
2.7. Genotypic characterization 
Total cellular RNA was extracted using the RNeasy minikit (Qiagen) and was subjected to RT-
PCR using primers NS3-F [5’-TTGGCTGCATCATCACTAGC-3’] (corresponding to nucleotides 1844 
to 1863 of accession number AJ242652) and NS3-R [5’-TTCTCCAGTGCTGGACAGAG-3’] 
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(corresponding to nucleotides 2822 to 2841 of accession number AJ242652) or NS5B-F [5′-
TGCTTTGACTCAACGGTCAC-3′] (corresponding to nucleotides 6649 to 6668 of accession number 
AJ242652) and NS5B-R [5′-TGTAACCAGCAACGAACCAG-3′] (7629 to 7648 of accession number 
AJ242652). Nucleotide sequences were determined by automated sequencing using BigDye 
terminator v. 3.1 (Applied Biosystems). 
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3. Results 
The in vitro antiviral activity of Tegobuvir, in combination with one or two other DAA, was 
evaluated in HCV replicon containing cells as follows: (i) short-term (three day) antiviral assays in 
which compounds were combined in checkerboard format, (ii) long-term resistance selection 
experiments, and (iii) clearance-rebound experiments. Tegobuvir and its close analogue GS-327073 
(Vliegen et al., 2009) inhibited HCV (genotype 1) subgenomic replicon replication in Huh 9-13, Huh 5-2 
and HuH6 cultures with mean EC50 values ranging between 1.2 – 43 nM. The in vitro anti-HCV activity 
of these imidazopyridines and the other molecules used in this study is summarized in Table 1 
(Supplemental 1). 
3.1. DAA combinations containing Tegobuvir result in an overall additive antiviral effect when 
evaluated in short-term (3 days) antiviral assays 
Tegobuvir was combined with either the protease inhibitor VX-950, the nucleoside polymerase 
inhibitor 2’-C-MeCyt or various non-nucleoside polymerase inhibitors (benzimidazole, benzofuran and 
Thiophene carboxylic acid analogues) in checkerboard format and assayed in HuH6 replicon 
containing cells. The antiviral effect was quantified after three days of treatment with the compounds. 
An overall additive antiviral activity was observed (as determined by the method of Prichard and 
Shipman (Prichard and Shipman, 1990) (Fig. 1. A-E). A slightly synergistic effect was observed when 
Tegobuvir, at concentrations <0.05 µM, was combined with the benzofuran site IV inhibitor HCV-796 
at concentrations <4.1 nM. 
3.2. DAA combinations containing Tegobuvir prevent or delay the development of drug-resistant 
variants 
When combined with the protease inhibitor VX-950 or various polymerase inhibitors (each at 
concentrations that were not able to clear the cells from their replicon), Tegobuvir (at concentrations of 
6, 30 or 150 nM) markedly delayed or completely prevented the emergence of drug-resistant variants 
following 3 weeks of culturing of replicon-containing Huh 9-13 cells [Fig. 2. A-E (i)]. At lower 
concentrations of either drug in the combination, replicons with low-level resistance to both drugs 
emerged [Fig. 2. A-E (ii)]. The nucleoside analogue, 2’-C-MeCyt did not select for resistant variants 
after three weeks of culturing (Fig. 2. B). The combination of 5x EC50 of tegobuvir with 5 x EC50 of VX-
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950 resulted in a very low number (i.e. 5) of colonies. Replicons replicating under this condition carried 
a signature mutation of VX-950 (A156S) and one for GS-9190 (C445F). Interestingly, VX-950 
mutations that appeared in the double resistant replicons differed from those that developed under 
VX-950 monotherapy. The combination of 2 x EC50 of the benzimidazole site I non-nucleoside inhibitor 
JT-16 with either 5 x EC50 or 25 x EC50 of Tegobuvir (Fig. 2. C) resulted respectively in a very low 
number (i.e. 3) or no drug-resistant clones. Genotypic analysis revealed that the double resistant 
clones carried a Tegobuvir-resistant mutation (C445F) and a JT-16-associated mutation (T389P/S 
(Delang et al., 2012)). The combination of 25 x EC50 of site II non-nucleoside inhibitor TCA and 5 x 
EC50 of Tegobuvir (Fig. 2. D) completely prevented the emergence of drug-resistant variants. The 
combination of 25 x EC50 of the benzofuran site IV non-nucleoside inhibitor HCV-796 with Tegobuvir 
resulted in either a reduction of the number of replicating clones at lower Tegobuvir concentration (5 x 
EC50) or a complete inhibition of viral replication at higher concentration (25 x EC50). Double resistant 
clones were found to carry a signature mutation (C316Y) for HCV-796 and the Tegobuvir mutation 
C445F. 
3.3. Combinations containing sub-optimal concentrations of Tegobuvir are able to completely clear 
hepatoma cells from HCV replicon 
When used alone at 25 x EC50 (concentrations that were not cytostatic), each DAA was able to 
produce a pronounced reduction in replicon replication after one passage (4 days). Tegobuvir, at a 
concentration of 150 nM (125 x EC50), was able to cure the cells from HCV RNA after 3 passages 
under the conditions used in this experiment (Fig. 3. A). At a lower concentration (25 x EC50), 
Tegobuvir treatment selected for a small number of colonies that were able to proliferate (Fig. 3. A). 
Genotyping of the HCV replicon RNA isolated from the surviving cells identified a mutation at position 
445 in NS5B (from cysteine to phenylalanine) that existed as a mixed population with the wild-type 
sequence (C445F/C), at passages C2R4 and C3R4. At later passages (C4R4 and C5R4), only 
phenylalanine was detected in the population. At concentrations of 12.5-fold of their respective EC50, 
the combination of Tegobuvir (15 nM) and 2’-CMeCyt (5.4 µM) cured cells from their replicon after only 
4 passages (Fig. 3. B). The combination of VX-950 (6.3 µM) and Tegobuvir (15 nM) cured cells from 
their replicon after only 1 passage whereas for the combination of VX-950 (6.3 µM) and 2’-C-MeCyt 
(5.4 µM) it took 2 passages to cure the cells. When Tegobuvir, at concentrations as low as 8.3-fold of 
its EC50 value (10 nM), was combined with 2’-C-MeCyt and VX-950 (8.3 x EC50) the triple combination 
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was able to cure cultures from their replicon after only 1 passage. In contrast, when used alone at 3-
fold higher concentrations (i.e. 25 x EC50), none of the inhibitors was able to cure the cells from HCV 
replicon even after 6 consecutive passages in the presence of the inhibitor. 
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4. Discussion  
We explored, using various protocols, the in vitro anti-HCV activity of Tegobuvir when combined 
with various DAAs including a protease inhibitor, a nucleoside polymerase inhibitor and 3 non-
nucleoside polymerase inhibitors each interacting with a different allosteric site on the enzyme. Short 
term 3-day combination experiments of Tegobuvir with each DAA tested, resulted in an overall additive 
antiviral activity. The results from this short term combination study thus indicated that none of the 
combinations containing Tegobuvir resulted in an antagonistic effect and that the efficacy of such 
combinations could be explored further. 
We here studied the effect of combinations that contain Tegobuvir on resistance development 
under long-term culture conditions. Our results demonstrate that Tegobuvir delayed or prevented the 
development of drug-resistant variants to other DAAs. This finding is important as monotherapy with 
most DAAs rapidly selects for resistant variants. Overall, combinations of Tegobuvir with another DAA 
(either a protease inhibitor, nucleoside or non-nucleoside NS5B inhibitor) had a marked effect on the 
emergence of drug-resistant (either mono- or double resistant) mutants. Interestingly, when double 
resistant mutants appeared, the mutations of such variants were not merely the sum of the mutations 
of the single resistant genomes. For example VX-950 alone (at 5x the EC50 concentration) resulted in 
the appearance of the V36V/A and T54T/A mutations [both described as being low- to medium-level 
resistance mutations (Sarrazin et al., 2007)]. In the combination VX-950 (5x EC50) and Tegobuvir (5x 
EC50) the A156S VX-950
res
 mutation appeared. A mutation at this position leads to high-level VX-950 
resistance (Sarrazin et al., 2007). Thus, suboptimal dosing of both Tegobuvir and VX-950 led to high 
level resistance mutations to VX-950 but low level resistance mutations to Tegobuvir. In the 
combination of 2’-C-MeCyt and Tegobuvir, despite the fact that the nucleoside only made limited 
contribution to replicon clearance, the observed resistance mutations to Tegobuvir  changed from 
C445F in the mono-treatment to C316C/Y + C445F in the combination treatment. Whereas C445F 
resulted in low level resistance to Tegobuvir, the addition of the C316C/Y to C445F resulted in a much 
more pronounced resistant phenotype (Shih et al., 2011). Surprisingly, the C445C/F mutation was also 
observed following treatment with JT-16, a site I non-nucleoside NS5B inhibitor whose binding pocket 
does not involve the 445 residue. Clonal sequencing of RNA from the replicon cells revealed that the 
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C445F mutation pre-exists at a frequency of 3.4% (Delang et al., 2011). Moreover, replicons carrying 
this mutation were markedly more fit when compared to wild-type replicons (Delang et al., 2011). 
Altogether, these observations suggest that, in addition to result in low-level resistance to Tegobuvir, 
C445F also appears to increase fitness of replicon RNA in a compound independent manner and was 
therefore enriched along with drug-specific resistance mutations that caused a loss of replicon fitness, 
as in the case of the mutations to JT-16.  
The ultimate goal of HCV therapy is to reduce viral replication and prevent the emergence of drug-
resistant variants so that there is no relapse when therapy is stopped. We therefore compared the 
anti-HCV activity of Tegobuvir either alone or in combination with other DAAs in the in vitro clearance-
rebound experiments. Replicon containing cells were treated with DAA combinations for extended 
periods of time in the absence of G418 selection. In the case that the antiviral combination was highly 
effective and replicon RNA was completely eradicated from the cells, the cells were no longer able to 
survive G418-induced killing after DAA treatment was terminated and G418 was added back to the 
culture medium. However, in such case that the antiviral treatment was not able to completely cure the 
cells from their replicon or that drug-resistant variants emerged, the hepatoma cells will be able to 
survive in the presence of G418. The combination containing Tegobuvir together with the protease 
inhibitor VX-950 and the nucleoside NS5B inhibitor 2’-C-MeCyt resulted in fast clearance of replicon 
HCV RNA. In fact, only 2 passages of combined compound pressure (each at 8.3x their EC50 
concentrations) were needed to achieve this. Combinations with slightly higher concentrations (12.5x 
EC50 instead of 8.3x EC50) of Tegobuvir and the protease inhibitor VX-950 (without the need for 2’-C-
MeCyt) cleared cells from their replicon after one single passage of combined compound pressure. 
The clearance-rebound experiments provide support for a triple therapy containing Tegobuvir.  
 In summary, we have demonstrated in HCV replicon-containing cells that combinations of 
Tegobuvir with other DAAs are effective in curing cells from HCV replicon and in delaying or 
preventing the development of resistance against other DAA. These results support further 
development of Tegobuvir-containing IFN-free, DAA combination regimens.  
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Table 1. In vitro antiviral activity of Tegobuvir and selected DAAs against HCV genotype 1b replicons. 
Inhibitor 
EC50 (µM) 
CC50 (µM) 
Huh 9-13 
a 
Huh 5-2 
a
 HuH6 
a 
Tegobuvir 0.0012 ± 0.0006 0.0054 ± 0.0018 0.043 ± 0.035 ≥ 24 
GS-327073 0.002 ± 0.004 0.0041 ± 0.0017 0.047 ± 0.018 17 
2’-C-MeCyt 0.43 ± 0.35 3 ± 1.5 1.02 ± 0.44  26  
JT-16 1.5 ± 0.83 0.80 ± 0.37 1.2 ± 0.47 22 
TCA 0.12 ± 0.0067 0.29 ± 0.049 0.27 ± 0.032 >33 
HCV-796 0.094 ± 0.045 0.042 ± 0.011 0.011 ± 0.0033 > 33 
VX-950 0.58 ± 0.10 1.1 ± 0.71 1.4 ± 0.49  25 
ribavirin n.d. 7 ± 3 28 ± 16 > 33 
IFN 2b (IU/ml) 20 ± 9 7 ± 5 22 ± 5 >500 
Data are mean values ± SD from at least 2 independent experiments 
n.d.: not determined 
a
 as determined by a luciferase (Huh 5-2) or RT-qPCR assay (Huh 9-13, HuH6) 
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Table 2: Mean volume of synergy (or antagonism) of Tegobuvir combined with: 
Mean volume of synergy or antagonism in µM²% (log volumes) 
Tegobuvir in combination with 
IFNα 2b Ribavirin VX-950 
2’-C-
MeCyt 
JT-16 TCA HCV-796 
2 (-0.4) 4 (-0.87) 0 (-5) 6 (0) 0 (0) 1 (-3) 35 (0) 
We here use a dissimilar site assumption of additivity, e.g. that two drugs affected dissimilar sites on a target enzyme or enzymes (Prichard and 
Shipman, 1990) . Volumes of synergy or antagonism under 25 µM²% (log volumes <2) at 95% confidence should be regarded as additive, 25-50 
µM²% (log volumes >2 and <5) minor but significant amount of synergy/antagonism, 50-100 µM²% (log volumes >5 and <9) moderate 
synergy/antagonism and >100 µM²% (log volumes >9) strong synergy/antagonism 
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FIGURE LEGENDS 
 
Fig. 1. Combined antiviral effect of Tegobuvir with a selection of HCV inhibitors in short-term (3 days) 
antiviral assays in replicon-containing HuH6 cells (Prichard and Shipman, 1990). The different gray 
scales represent different ranges of values: dark grey: −20% to 0%, light grey: 0% to 20%. Values 
under the zero plane indicate antagonistic activity, values in the zero plane indicate additive activity, 
and values above the zero plane indicate synergistic activity. All data points are averages of at least 
two independent experiments. Mean volumes of synergy or antagonism in brackets are presented on 
95% confidence values; mean volumes between -25 and +25 indicate an additive effect– mean 
volumes from >25 to <50 indicate slight synergism. 
 
Fig. 2. Combined Resistance Selection. Huh 9-13 cells were treated with Tegobuvir alone or in 
combination with VX-950 (A), BILN 2061 (B), JT-16 (C), HCV-796 (D) or TCA (E) at the indicated 
concentrations in the presence of 1 mg/ml G418. When confluent, or when a sufficiently large number 
of colonies had developed, cells were further passaged under the same experimental conditions. 
Following 5 passages, cultures were fixed (i) stained with Giemsa and (ii) phenotyped or genotyped. 
Published resistance mutations are marked in red. Sequences were collected for NS3 from AA 35-328 
(VX-950) and NS5B from AA 242 to 540 (all combinations tested). n.d.: not determined – cells died 
during culture. †: cells died during combined resistance selection. 
 
Fig. 3. Effect of Tegobuvir-containing combinations on the clearance of replicons from Huh 9-13 cells. 
Clearance and rebound phase data from six consecutive clearance passages [C1→C6] (in the 
presence of fixed concentrations of either one (A), two (B) or three compounds (C)) each followed by 4 
consecutive rebound passages [R1→R4] (with G418 pressure and without compound pressure). Data 
are expressed as percentage of untreated controls (UTC). 
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A (i)  
 
A. 
(ii)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
B (i) 
 
B. 
(ii)
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
22 
 
C (i) 
 
C. 
(ii)
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
23 
 
D (i) 
 
D. (ii) 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
24 
 
E (i) 
 
E. (ii) 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
25 
 
Fig. 3.  
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